11. MAO-A, MAO-B
MAO-A MAO-B
Acts on NE, 5HT
DA, tyramine
Phenylethylamine
and trace amines
DA, tyramine
Mnemonic A for All Beer for DTs
Location Brain Brain
Gut, liver Platelets
Placenta,
skin
Lymphocytes
13. TRANYLCYPROMINE (TCP)
– First clinical trial in 1959
– Introduced as an antidepressant in 1962
– Temporarily withdrawn in 1964 because of the
cheese reaction; later reintroduced
– Available in USA and Europe (Parnate)
14. • Meta-analysis shows that
– TCP>placebo (5 studies)
– TCP=other ADs (18 studies)
– TCP=other ADs in resistant depression (4 studies)
• Also
– TCP effective in atypical depression (many studies)
– TCP effective in bipolar depression with ? low risk
of switch
– May improve negative s/s in schizophenia
TRANYLCYPROMINE (TCP)
17. ADVERSE EFFECTS
• Commonest AEs are adrenergic AEs
– Dry mouth
– Insomnia
• Also common: dizziness/postural hypotension,
transient palpitations after dosing, sedation
• No increase in appetite, weight
• Few/no sexual AEs
• No dependence potential
• Need to taper and stop
18.
19. MAOIs and Indian food
• Case reports of tyramine reaction with Indian food---
ZERO
25. • Pizza with plain mozzarella cheese---OK
• Veggie pizza----OK
• Pepperoni (fresh) pizza---OK
• Cottage cheese - OK
Schulman and Walker (1999)
26. Beverages: Good news
• Bottled beer: one or two 330 mL bottles per day
• White wine (preferred): one or two glasses (100 to
120 mL) per day
• Red wine: Better to avoid
May cause benign headache
28. Far-Eastern
Tyramine-containing soya-related items:
• Fermented soya bean
• Fermented tofu
• Tofu kept in the fridge for a few days
• Chilli soyabean paste
• Soyabean paste
• Miso
Wing and Chen (1997). PMID: 9169972
29. Use with caution or
avoid in
• Patients with unstable medical comorbidity
• Severe CVS disorders
• High BP
• Liver disease
• Severe renal disease
• Patients who may not adhere to diet/drug
guidelines
• Pregnancy and lactation
30. TCP: PHARMACOKINETICS
• Half-life, 2 h
– So trough levels during treatment are nearly 0.
– So washout in <1 day.
– So monoamine release, monoamine reuptake
mechanisms may be unimportant.
• Steady-state is unnecessary because MAO
inhibition is irreversible.
• Distributed in all organ systems.
32. Implications of irreversibility
• For duration of action
– For dietary restrictions
– For drug interactions
– For change of treatment
• New enzyme must be synthesized
– First the MAOI must be washed out
– Then, it takes 1-2 weeks for new MAO to be
synthesized and to reach adequate levels
33. TCP: DRUG INTERACTIONS
• Sumatriptan, rizatriptan, almotriptan are
metabolized by MAO-A
– Almotriptan is also metabolized by CYP enzymes
• Use lower doses in patients receiving TCP.
• Avoid concomitant other antidepressants
• Nicotine use
• Benzodiazepines, Valproate
34. DOSING
• Start at 30 mg/day in divided doses.
• If no response, increase by 10 mg/day every 1-
3 weeks.
• Usual dose, 40-60 mg/day
• Maximum dose, 60 mg/day in divided doses.
– Divided dosing reduces AEs such as dizziness,
postural hypotension, etc.
Editor's Notes
Adverse effects of tranylcypromine (n = 63 patients) in a placebo (n = 59) and nortriptyline (n = 61) controlled, randomized, double-blind, short-term trial with intensive study of adverse effects and including mild-to-moderate severity (significant differences of tranylcypromine vs. nortriptyline for dizziness (p < 0.05), insomnia (p < 0.01) and overexcitement (p < 0.05) and tranylcypromine vs. placebo for dizziness, insomnia and dry mouth (p < 0.01); 4.5 adverse effects per patient for tranylcypromine, 4.8 nortriptyline and 2.3 placebo (nonsignificant))
Adverse effects of TCAs (n = 128 patients), SSRIs (n = 30), MAO inhibitors (n = 36, 61% tranylcypromine) and atypical antidepressants (n = 14, 71% bupropion) in an open, non-interventional, long-term trial with intensive study of adverse effects and including mild to moderate severity (mean number of adverse effects per visit = 2.6), comparison tranylcypromine vs. SSRIs: sedation and headache (p < 0.01 each), dry mouth, anxiety, nausea and sweating (p < 0.001 each), 61.5%, 16.4%, 37.4% and 17.5% of patients with treatment of TCAs, SSRIs, tranylcypromine and bupropion, respectively, received lithium augmentation